Regeneron Pharmaceuticals (REGN) analysis

Loading the Vaultflake…

Health is the lab's cash, not the full Dupixent invoice at the pharmacy. Quality separates Regeneron's piece from development that does not sell yet. Growth follows the volume the payer covers, not a platform that always hits. P/E is read against a year of Eylea exclusivity, not against that year as normal. Shareholder return, if any, comes out of that piece. Do not read it as intellectual property that closes the market.

The P/E of a year without a biosimilar is not the earnings once the price falls. EV/EBITDA is read on Regeneron's piece, not on the whole Dupixent sale. Do not use Sanofi's multiple as if the agreement did not split the result. A dash if the REGN cache is cold.

Limits of this report

Not advice on Regeneron. Vaultflake does not state the Sanofi split or treat the patent as a wall. Read the filings. A past dividend is not a right. The table is a snapshot, not a target price.

Questions from this report